John Ruesch - Astria Therapeutics Senior Operations

Astria Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2694) % which means that it has lost $0.2694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4315) %, meaning that it created substantial loss on money invested by shareholders. Astria Therapeutics' management efficiency ratios could be used to measure how well Astria Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2026. Return On Capital Employed is likely to drop to -0.33 in 2026. At this time, Astria Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 9.3 M in 2026, whereas Return On Tangible Assets are likely to drop (0.26) in 2026.

Similar Executives

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Astri Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. Astria Therapeutics (ATXS) is traded on NASDAQ Exchange in USA and employs 78 people. Astria Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Astria Therapeutics Leadership Team

Astria Stock Performance Indicators

Additional Tools for Astria Stock Analysis